Clinical Trials in Ramat Gan, Israel
280 recruiting
Showing 1–20 of 370 trials
Recruiting
Phase 1Phase 2
Safety of HRX215 in Patients After Minor and Major Liver Resection
Liver ResectionColorectal Carcinoma Liver Metastases
HepaRegeniX GmbH80 enrolled6 locationsNCT06638502
Recruiting
Phase 2
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Small Cell Lung Cancer
AbbVie180 enrolled52 locationsNCT07155174
Recruiting
Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Triple-Negative Breast CancerPancreatic CancerNon-small Cell Lung Cancer+4 more
AbbVie694 enrolled46 locationsNCT05005403
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled428 locationsNCT05980949
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled255 locationsNCT06937229
Recruiting
Phase 3
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
CandidemiaCandidiasis, Invasive
Basilea Pharmaceutica450 enrolled143 locationsNCT05421858
Recruiting
Phase 3
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
Hereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
ADARx Pharmaceuticals, Inc.90 enrolled51 locationsNCT06960213
Recruiting
Phase 1Phase 2
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC200 enrolled4 locationsNCT07519772
Recruiting
Phase 1Phase 2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled80 locationsNCT06863272
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled286 locationsNCT06925737
Recruiting
Phase 2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC594 enrolled127 locationsNCT06890884
Recruiting
Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
AbbVie380 enrolled166 locationsNCT06158841
Recruiting
Phase 1Phase 2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
Sanofi258 enrolled26 locationsNCT04643002
Recruiting
Phase 3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled200 locationsNCT07195695
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled183 locationsNCT07060807
Recruiting
Phase 1Phase 2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC450 enrolled46 locationsNCT04165070
Recruiting
Phase 1
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Advanced Solid TumorsMetastatic Solid Tumors
Merck Sharp & Dohme LLC178 enrolled25 locationsNCT05853367
Recruiting
Phase 3
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Urothelial CarcinomaUpper Urinary Tract Urothelial Carcinoma
UroGen Pharma Ltd.70 enrolled62 locationsNCT06774131
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled172 locationsNCT06824467